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C
ell migration is a rate-limiting event in skin 
wound healing. In unwounded skin, cells are 
nourished by plasma. When skin is wounded, 
resident cells encounter serum for the ﬁ  rst time. As the 
wound heals, the cells experience a transition of serum 
back to plasma. In this study, we report that human 
  serum selectively promotes epidermal cell migration and 
halts dermal cell migration. In contrast, human plasma 
promotes dermal but not epidermal cell migration. The 
on-and-off switch is operated by transforming growth 
factor (TGF) β3 levels, which are undetectable in plasma 
and high in serum, and by TGFβ receptor (TβR) type II 
levels, which are low in epidermal cells and high in 
  dermal cells. Depletion of TGFβ3 from serum converts 
serum to a plasmalike reagent. The addition of TGFβ3 to 
plasma converts it to a serumlike reagent. Down-regulation 
of TβRII in dermal cells or up-regulation of TβRII in 
  epidermal cells reverses their migratory responses to 
  serum and plasma, respectively. Therefore, the naturally 
occurring plasma→serum→plasma transition during 
wound healing orchestrates the orderly migration of 
  dermal and epidermal cells.
Introduction
It is estimated that each year >7 million people develop chronic 
nonhealing wounds, including pressure, leg, and diabetic ulcers 
and burns, in the United States. These wounds require long-
term care that is labor intensive and costly. Delayed wound 
healing among the elderly in the United States, for instance, is 
estimated to cost >$9 billion each year (Wadman, 2005). 
  Although tremendous efforts were made on the development of 
recombinant growth factors (GFs) and organotypic skin equiva-
lents, the overall outcomes of GF treatments or the use of skin 
substitutes, such as xenografts, have not generated satisfactory 
cost-effective benefi  ts (Boyce et al., 1995; Cross and Mustoe, 
2003). Few of the GFs have ultimately received approvals from 
the Food and Drug Administration. Therefore, there is a pressing 
need to better understand the fundamentals of the skin wound-
healing processes.
Skin wound healing is a complex process involving 
  collaborative efforts of multiple types and lineages of skin cells, 
ECMs, and soluble GFs. Infl  ammation, reepithelialization, tissue 
Correspondence to Wei Li: wli@usc.edu; or David T. Woodley: dwoodley@usc.edu
Abbreviations used in this paper: AG, average gap; BPE, bovine pituitary 
  extract; DF, dermal ﬁ  broblast; GF, growth factor; HDMEC, human dermal micro-
vascular endothelial cell; HK, human keratinocyte; MC, melanocyte; MI, migra-
tion index; siRNA, short inhibitory RNA; TβR, TGFβ receptor.
Correspondence to Wei Li: wli@usc.edu; or David T. Woodley: dwoodley@usc.edu
Abbreviations used in this paper: AG, average gap; BPE, bovine pituitary 
  extract; DF, dermal ﬁ  broblast; GF, growth factor; HDMEC, human dermal micro-
vascular endothelial cell; HK, human keratinocyte; MC, melanocyte; MI, migra-
tion index; siRNA, short inhibitory RNA; TβR, TGFβ receptor.
formation, and tissue remodeling are proposed sequential events 
to heal skin wounds (Martin, 1997; Singer and Clark, 1999). 
Abnormalities in any of the events could result in nonhealing 
wounds or healed wounds with hypertrophic scars (Tredget 
et al. 1997). Throughout these processes, cell motility control is 
critical. The epidermal cells, largely keratinocytes, laterally 
  migrate across the wound bed from the cut edge to   resurface the 
wound in the process known as reepithelialization. The human 
dermal cells, including dermal fi  broblasts (DFs) and dermal 
  microvascular endothelial cells (HDMECs), move into the 
wound to produce and deposit large amounts of matrix   proteins, 
to contract and remodel the wound, and to build new blood 
  vessels. Thus, it is critical to understand what cells move into the 
wound fi  rst, second, or third and what mechanism   orchestrates 
the   order of the multitype skin cell motility during wound healing.
In unwounded skin, the resident skin cells are nourished 
by a fi  ltrate of plasma. When skin is wounded, the resident cells 
in the wound encounter an acute transition from an initial stage 
of plasma to a stage of serum for the fi  rst time. As the wound 
heals and subsequent wound remodeling initiates, the resident 
cells experience a transition from plasma back to serum. 
In fact, the plasma→serum→plasma transition coincides with 
the   classical phases of skin wound healing, as mentioned in the 
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the physiological function of this transition in the wound 
repair. In addition, the full ingredients in wound fl  uid may be
more complex than those in plasma or serum. For instance, it 
should also contain released factors from infl  ammatory leuko-
cytes and even from the resident skin cells (Coulombe, 2003). 
In particular, the infl  ammatory cells and factors have long been 
proposed to play important roles in the repair process.  However, 
recent studies suggest that infl  ammation, which is a   necessary 
mechanism of defense in adults, is not only dispensable for 
wound healing but rather harmful to the purposes of fast heal-
ing and less scaring. First, embryos, in which no infl  ammation 
takes place, heal wounds perfectly without a scar (Ferguson 
and O’Kane, 2004). Second, Smad3 and Pu.1 knockout mice 
cannot mount an infl  ammatory response; however, the reepi-
thelialization and wound healing occur faster than their wild-
type littermates and show less scaring (Ashcroft et al., 1999; 
Martin et al., 2003).
We recently reported that human serum, but not human 
plasma, promotes human keratinocyte (HK) migration (Henry 
et al., 2003). This suggested, for the fi  rst time, that the plasma 
to serum transition differentially regulates skin cell motility. In 
the present study, we studied the effects of plasma versus serum 
on the motility of three primary human skin cell types: DFs, 
HDMECs, and HKs. Our results suggest that the plasma→
  serum→plasma transition serves as a “traffi  c control” for the 
  dermal and epidermal cell motility, in which TGFβ3 in serum 
acts as the “traffi  c controller” and the cell surface levels of 
type II TGFβ receptor (TβRII) operate as the “sensor” to deter-
mine the order of skin cell migration.
Results
Human plasma and serum have opposite 
effects on dermal and epidermal 
cell motility
Human DFs, HDMECs, and HKs are the three major types of 
skin cells involved in wound healing. During the wound heal-
ing, either human plasma or serum represents the main source 
of soluble GFs in the wound fl  uid. Therefore, we studied the 
migratory responses of these three cell types to human plasma 
and serum. The individual cell motility-based colloidal gold 
motility assay (Albrecht-Buehler, 1977) and a modifi  ed in vitro 
wound-healing assay (Li et al., 2004b) were performed side by 
side. In the colloidal gold motility assay, cells are allowed to at-
tach and migrate on an ECM-precoated colloidal gold surface in 
the presence of a cell proliferation inhibitor. As the cells move, 
they leave behind migration tracks that can be visualized under 
a microscope and added as a migration index (MI) by computer-
assisted analysis (Woodley et al., 1988). As shown in Fig. 1 A, 
in the absence of plasma or serum, all three types of skin cells 
modestly migrated on collagen (a, d, and g) and generated MIs 
(see Materials and methods) from 4 to 8. This is consistent with 
our previous study reporting that ECMs alone can initiate cell 
migration in the total absence of soluble GFs (Li et al., 2004c). 
The addition of human plasma strongly stimulated DF and 
  HDMEC migration (Fig. 1 A, b and e), generating MIs >25. 
The mean size migration tracks were marked with open circles. 
In contrast, human serum showed little stimulation of DF and 
HDMEC migration (Fig. 1 A, c and f) with MIs between 7 and 10. 
However, as previously described (Henry et al., 2003), plasma 
and serum showed opposite effects on HK migration. Plasma 
had a weak stimulation of HK migration (Fig. 1 A, h), with MIs 
of 9–11. In contrast, serum robustly stimulated HK migration, 
which left behind long and linear tracks (Fig. 1 A, i) with MIs 
of 28–30.
The results of the in vitro wound-healing assay, which 
measures the averaged and directional migration of a cell popu-
lation, confi  rmed the fi  ndings. The unclosed distance in multiple 
wounded areas in each cell culture well was measured and 
quantifi  ed as an average gap (AG). As shown in Fig. 1 B, plasma 
but not serum stimulated wound closure by DFs (Fig. 1 B, c vs. d) 
and HDMECs (Fig. 1 B, g vs. h). In contrast, human serum
but not plasma stimulated complete closure of the wounded 
area of HKs (Fig. 1 B, l vs. k). Therefore, the aforementioned 
data suggest that: (1) plasma contains a promotility factor for 
DFs and HDMECs but not for HKs; (2) as plasma converts to 
serum, serum acquires new factors that specifi  cally stimulate 
HK migration; and (3) serum stops stimulation of the dermal 
cell migration by losing the plasma promotility factors, by gain-
ing antimotility factors, or both. Therefore, we, investigated 
these possibilities.
TGF𝗃3 but not TGF𝗃1 or TGF𝗃2 in human 
serum determines the on and off of dermal 
versus epidermal cell migration
To identify the factors that determine the differential effect of 
plasma versus serum on dermal and epidermal cell motility, we 
focused on the possible antimotility factors of the dermal cells 
that should only be present in human serum. This approach 
was based on the assumption that serum should retain all the 
preexisting plasma factors in addition to acquired new factors 
during the plasma to serum transition. Therefore, we studied 
TGFβ, a well-characterized family of antigrowth and anti-
motility factors.
It is known that in human plasma, the levels of all three 
TGFβ isoforms are either low, such as TGFβ1, or undetectable, 
such as TGFβ2 and TGFβ3. In human serum, however, TGFβ1, 
TGFβ2, and TGFβ3 are all elevated to mean values of 30, 
1–1.5, and 1–2 ng/ml, respectively (Assoian et al. 1983; Rob-
erts, 1998; Grainger et al., 2000; Hering et al., 2001; Bellone 
et al. 2005). We tested whether depletion of the TGFβ function 
in serum would convert serum to plasma, regaining its promotil-
ity effect on the dermal cells. For simplicity, only the MIs of the 
colloidal gold cell migration experiments are presented. As shown 
in Fig. 2 A, plasma (bar 2) but not serum (bar 3) stimulated DF 
migration over the serum-free control (bar 1).   However, the 
  addition to serum of increasing amounts of pan–anti-TGFβ–
  neutralizing antibody, which neutralizes all three human TGFβ 
isoforms, completely converted the serum to a promotility  stimulus 
of DF migration just like plasma (Fig. 2 A, bars 4–6 vs. bar 3).
To determine further which TGFβ isoform was specifi  -
cally responsible for the inhibitory effect in serum, we made use 
of three isoform-specifi   c neutralizing antibodies under the 
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or TGFβ3 but show little cross-reacting activities. To our 
  surprise, the anti-TGFβ1 antibody failed to eliminate the inhibi-
tory effect of serum on DF migration even at 2.0 μg/ml, which 
is capable of blocking >50 ng/ml TGFβ1 (Fig. 2 A, bars 7–9 vs. 
bar 3). Just like the anti-TGFβ1 antibody, the addition of an 
anti-TGFβ2 antibody did not relieve the serum’s inhibitory 
 effect on DF migration (Fig. 2 A, bars 10–12 vs. bar 3). In contrast, 
the addition of an anti-TGFβ3 antibody completely converted 
serum to a plasmalike promotility stimulus for DFs (Fig. 2 A, 
bars 13–15 vs. bars 2 and 3).
The importance of TGFβ3 was confi   rmed by in vitro 
wound-healing assays. As shown in Fig. 2 B, the addition of 
 increasing amounts of anti-TGFβ3 antibody to serum eliminated 
its inhibitory effect on DF (c–e vs. b) and HDMEC (h–j vs. g) 
migration in a dose-dependent manner, resulting in closure of 
the wounded   areas. In contrast, the addition of the antibodies to 
Figure 1.  Plasma and serum oppositely affect dermal and 
epidermal cell migration. HKs, DFs, and HDMECs were serum 
starved overnight and subjected to colloidal gold migration 
assays (A) and in vitro wound-healing assays (B). (A) Repre-
sentative images of the colloidal gold migration assays under 
the following three conditions: (1) on a collagen matrix in the 
absence of any soluble GFs (a, d, and g); (2) on a collagen 
matrix in the presence of an optimal concentration (10% vol/vol) 
of human plasma (b, e, and h); and (3) on collagen matrix in 
the presence of an optimal concentration (10% vol/vol) 
of human serum (c, f, and l). The computer-assisted quantita-
tive analyses of the migration tracks are shown as migration 
indices (MI). These experiments were repeated ﬁ  ve times, and 
closely similar results were obtained. Average size migration 
tracks are marked with circles. (B) In vitro wound-healing 
  assay was performed under the same conditions. The wound 
closures were photographed, and the average gaps (AGs) 
were quantitated as described previously (Li et al., 2004b). 
AGs are indicated by lines and arrows; some gaps were too 
close to insert an arrow. Similar results were reproduced in 
three independent experiments.JCB • VOLUME 172 • NUMBER 7 • 2006  1096
serum had   neither stimulatory nor inhibitory effects on the 
  closure of the wounded HK cell monolayer (Fig. 2 B, m–o vs. l). 
Quantitation of the wound closures is shown below the corre-
sponding images as AGs. These data indicate that it is the 
 increased  TGFβ3 after plasma to serum transition that selec-
tively stops dermal cell migration.
To gain a reciprocal support of this fi  nding, we compared 
the effect of recombinant TGFβ3 on GF-induced migration of 
DFs, HDMECs, and HKs. As shown in Fig. 3, TGFα-stimulated 
HK migration (TGFα is used to stimulate HK migration because 
plasma does not stimulate HK migration and serum already con-
tains TGFβ3) was not affected by the addition of TGFβ3 (Fig. 3 A). 
In contrast, plasma-stimulated migration of DFs and HDMECs 
was blocked by the addition of TGFβ3 in a dose-dependent 
  manner (Fig. 3, B and C). Therefore, we conclude that along the 
steps of the plasma→serum→plasma transition during wound 
healing, TGFβ3 acts as an on-and-off switch to separate the 
  migration of dermal cells from that of epidermal cells.
Differential expression of T𝗃Rs in epidermal 
versus dermal cells
To investigate the molecular basis by which the migratory 
  responses of dermal and epidermal cells naturally divide them 
into either TGFβ-sensitive or TGFβ-insensitive cells, we exam-
ined the profi   les of three TβRs—TβRI/ALK5, TβRII, and 
TβRIII/betaglycan—in DFs, HDMECs, and HKs as well as in 
Figure 2. TGF𝗃3 but not TGF𝗃1 or TGF𝗃2 in human serum selectively blocks dermal cell migration. DFs, HDMECs, and HKs were serum starved overnight 
and subjected to migration assays on collagen in the absence or presence of plasma, serum, or serum with added increasing amounts of anti-TGFβ neutral-
izing antibodies. The four antibodies include a pan-antibody against all three TGFβ isoforms and three other antibodies speciﬁ  cally against the individual 
TGFβ1, TGFβ2, or TGFβ3. The amounts of these antibodies were predetermined to neutralize the same amounts of their corresponding TGFβ isoforms. 
(A) Anti-TGFβ3 antibody released the inhibition of serum in DF migration, whereas anti-TGFβ1 and anti-TGFβ2 antibodies did not. This experiment was re-
peated four times. Error bars represent SEM. (B) The addition of anti-TGFβ3 antibody to serum converted to a promotility agent for both DFs and HDMECs. 
The cells were subjected to in vitro wound-healing assays under either serum-free, serum, or serum with added anti-TGFβ3 neutralizing antibodies. After 
16 h, the wound closures were photographed, and the AGs were quantitated as described previously (Li et al., 2004b). AGs are indicated by lines and 
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melanocytes (MCs). As shown in Fig. 4 A, all four cell types 
expressed comparable levels of TβRI (a), with a similar level 
in HKs and DFs (lanes 1 and 3) and a slightly lower level in 
MCs and HDMECs (lanes 2 and 4). Among the four cell types, 
only DFs showed a detectable level of TβRIII/betaglycan (Fig. 
4 A, e; lane 3). Anti–β-actin antibody blotting of the lower part 
of the same membranes (Fig. 4 A, b, d, and f ) was used as the 
control for equal sample loading and the references for densi-
tometry scan quantitation (ratio of TβR/β-actin). It can be seen 
that there is no apparent correlation between TβRI and TβRIII 
expression (note that HDMECs show no expression of TβRIII 
and yet are sensitive to TGFβ) and TGFβ sensitivity between 
the dermal and epidermal cells (the migration of MCs responds 
to plasma and serum just like HKs; not depicted). In contrast, 
there is a clear correlation between the levels of TβRII expres-
sion and the sensitivity of dermal and epidermal cell migration 
to TGFβ. The TGFβ-sensitive DFs and HDMECs exhibited 
5–12-fold higher levels of TβRII than TGFβ-insensitive HKs 
and MCs (Fig. 4 A, c; lanes 3 and 4 vs. lanes 1 and 2) based on 
their anti–β-actin antibody blotting controls (Fig. 4 A, d).
To confi  rm the TβR expression patterns in human skin, 
sections of frozen normal human skin were subjected to (1) 
 indirect  immunofl  uorescence staining with the corresponding 
anti-TβR antibodies, (2) DAPI staining (to strain the nuclei); 
and (3) phalloidin (to stain F-actin) or IgG control (control for 
anti-TβR antibodies). As shown in Fig. 4 B, the control IgG 
  antibodies showed little staining in either the epidermal or the 
dermal areas (e, j, and o). In contrast, anti-TβRI antibody staining 
showed the expression of TβRI in both the epidermis and  dermis 
(Fig. 4 B, a). This staining colocalized with phalloidin (mem-
brane and cytosol) but not DAPI (nuclei), resulting in the yellow/
orange-colored area when the images were merged (Fig. 4 B, 
d vs. b and c). Consistent with the Western blot data, the anti-
TβRII antibody staining clearly showed stronger expression of 
the TβRII in the dermis than the epidermis (Fig. 4 B, f). The 
staining colocalized with phalloidin, resulting in a merged yellow/
orange color in the dermis and less in the epidermis (Fig. 4 B, i). 
As expected, anti-TβRIII antibodies almost entirely stained the 
dermis (Fig. 4 B, k). No merged yellow/orange color was de-
tected in the epidermis (Fig. 4 B, n vs. i and m).
We questioned whether the difference in TβR   profi  les 
 affects the TGFβ-stimulated phosphorylation of Smad2/3  between 
dermal and epidermal cells. As shown in Fig. 4 C, the dose-
  dependent analyses showed little differences in TGFβ- induced 
Smad2/3 phosphorylation (ser-465/467) in all three cell types, 
in which the induced Smad2/3 phosphorylation could be clearly 
detected after stimulation with 0.1–0.5 ng/ml TGFβ3 (lanes 3 
and 4). Moreover, as shown in Fig. 4 D, we also detected similar 
kinetics of TGFβ3-induced Smad2/3 phosphorylation in both epi-
dermal (HKs) and dermal cells (DFs and HDMECs). Close ana-
lyses of the data from multiple experiments revealed a relatively 
sustained Smad2/3 phosphorylation in HKs and a transient Smad2/3 
phosphorylation, which declined after 45 min of TGFβ3 stimula-
tion in DFs and HDMECs (Fig. 4 D, c and e vs. a). Therefore, the 
insensitivity of HKs to the antimotility   effects of human serum 
or TGFβ3 was not caused by a complete lack of or a signifi  cant 
difference in TGFβ3-stimulated Smad2/3 phosphorylation.
The lower T𝗃RII level in epidermal cells 
selectively blocks the antimotility signal 
of human serum or TGF𝗃3
The critical question was whether the differences in TβR 
 expression,  especially  TβRII, account for the differential 
 migratory responses of the dermal and epidermal cells to plasma 
and serum. We took the following approaches: (1) to increase 
the TβR levels in epidermal cells to similar levels in the dermal 
cells and (2) to down-regulate the TβR expression in the dermal 
Figure 3. TGF𝗃3 selectively inhibits dermal, but not epidermal, cell 
  migration. DFs, HDMECs, and HKs were serum starved overnight and sub-
jected to colloidal gold migration assays on collagen. The indicated con-
centrations of TGFβ3 were added to either TGFα- (stimulus of HK migration 
to replace serum that already contains TGFβ3) or plasma (stimulus of DF 
and HDMEC migration)-containing media. MIs of the migration are shown. 
The differences in MIs in HKs were statistically insigniﬁ  cant (P < 0.001). 
The differences in MIs in DFs and HDMECs were statistically signiﬁ  cant 
(P < 0.005). These experiments were repeated four times, and reproduc-
ible results were obtained. Error bars represent SEM.JCB • VOLUME 172 • NUMBER 7 • 2006  1098
cells to similar levels seen in the epidermal cells. Then, we 
tested whether these changes would convert the TGFβ-insensitive 
epidermal cells to TGFβ-sensitive dermal cells and vice versa. 
To overexpress the TβR of interest, we chose to use lentiviral 
vector pRRLsinhCMV (Li et al., 2004a,b). Using the EGFP 
gene as the marker, as shown in Fig. 5 A, we provide   evidence 
that this gene delivery system offers >90% gene transduction 
effi  ciency in all four human skin cell types.
To study the role of TβRII, we focused on HKs, which 
showed a much lower level of TβRII than dermal cells, DFs, and 
HDMECs. As shown in Fig. 5 B, HKs express a lower level of 
TβRII than DFs or HDMECs (a; lane 2 vs. lanes 1 and 3).  However, 
after pRRLsinhCMV-TβRII virus infection, the TβRII expression 
in HKs was increased to a similar level seen in DFs and HDMECs 
(Fig. 5 B, lane 5 vs. lanes 1 and 3). The kinase-defective TβRII 
mutant (TβRII-KD) was included as the control for specifi  city. As 
shown in Fig. 5 D, the exogenously expressed TβRII-KD (lane 3) 
was equivalent to the exogenously expressed wild-type TβRII 
(lane 2). As expected, overexpression of TβRII-KD but not wild-
type TβRII blocked TGFβ3-stimulated Smad2/3 phosphorylation 
(Fig. 5 C, lanes 5 and 6 vs. lanes 3 and 4 and lanes 1 and 2). 
To study TβRIII, we infected HKs with pRRLsinhCMV-TβRIII 
  virus. As shown in Fig. 5 E, the TβRIII expression in HKs was 
  elevated from a nondetectable level in uninfected HKs (lane 3) to a 
similar level observed in DFs (lane 4 vs. lane 2). DFs are the only 
skin cell type expressing a detectable level of TβRIII.
Figure 4.  In vitro and in vivo human skin proﬁ  les of T𝗃Rs (I, II, and III) and their transmission of TGF𝗃-stimulated Smad2/3 activation. (A) Equal amounts of 
cell lysates of serum-starved HKs, MCs, DFs, and HDMECs were resolved in three SDS gels and subjected to Western blot analyses with antibodies against 
TβRI/ALK5 (a), TβRII (c), or TβRIII/betaglycan (e). Each lower part of the three membranes was blotted with an anti–β-actin antibody as a control (b, d, 
and f). The expression was quantitated by a densitometry scan, giving rise to a ratio of TβR band intensity over its corresponding β-actin band   intensity. 
(B) Normal human skin sections were subjected to indirect immunoﬂ  uorescence staining with the antibodies against TβRI (a), TβRII (f), TβRIII (k), DAPI (b, g, 
and l), rhodamine-conjugated phalloidin (c, h, and m), or corresponding IgG controls (see Materials and methods). The images show skin tissue distribution 
of the TβRs (a, f, and k), nuclei (b, g, and l), F-actin (c, h, and m), and all three stains merged (d, i, and n). A section of the anti-TβRI antibody staining 
(a, dotted box) was enlarged in the inset to visualize cellular levels of staining. Bar, 20 μm. (C) The cells were either untreated or treated with the indicated 
concentrations of TGFβ3 for 15 min, and equalized cell lysates (40 μg/lane) were subjected to Western blot analyses with either   antiphospho-Smad2/3 
(a, c, and e) or anti-Smad2/3 (b, d, and f) antibodies. (D) The cells were either untreated or treated with 2.5 ng/ml TGFβ3 for the i  ndicated periods of time. 
Equalized cell lysates were subjected to Western blot analyses with either antiphospho-Smad2/3 (a, c, and e) or anti-Smad2/3 (b, d, and f) antibodies.TGFβ3 DETERMINES SKIN CELL MOTILITY ORDER • BANDYOPADHYAY ET AL. 1099
These TβRII and TβRIII expression-equalized HKs were 
subjected to migration assays in response to plasma, serum, or 
TGFα in the absence or presence of TGFβ3. As shown in 
Fig. 5 F, migration of the parental HKs was unchanged by 
plasma (bar 2 vs. bar 1), dramatically stimulated by serum or 
TGFα (bars 3 and 4), but not blocked by the addition of TGFβ3 
(bar 5 vs. bar 4). In contrast to the parental HKs, the TβRII-
overexpressing HKs responded to serum as a strong antimotil-
ity reagent (Fig. 5 F, bar 8 vs. bar 3). Moreover, TGFβ3 
completely blocked the TGFα-stimulated migration of these 
cells (Fig. 5 F, bar 10 vs. bar 9). However, overexpression of 
the TβRII-KD mutant did not show the same effect. The migra-
tion of TβRII-KD–HK cells, like the parental HKs, could still 
be stimulated by serum (Fig. 5 F, bar 13 vs. bar 3), and the 
TGFα-stimulated migration remained refractory to the  presence 
of TGFβ3 (Fig. 5 F, bar 15 vs. bar 4).
The migration of TβRIII-overexpressing HKs was slightly 
inhibited by serum (Fig. 5 F, bar 18) in comparison with their 
  parental counterpart (Fig. 5 F, bar 3; P < 0.001). TGFβ3 also 
 partially  blocked  TGFα-driven migration of the cells (Fig. 5 F, bar 
20 vs. bar 5; P < 0.005). It is possible that TβRIII overexpression 
allows HKs to have more access to the TGFβ3 that is bound to the 
exogenously overexpressed TβRIII. Based on our previous study 
that TGFβ selectively blocks the proliferation but not migration of 
HKs in response to GFs (Sarret et al., 1992), the aforementioned 
fi  nding indicates that it is the lower TβRII level that determines 
HKs’ sensitivity to the antiproliferation but not the antimotility 
 signal  of  TGFβ3.
To further verify the key role of TβRII, we generated 
TβRII- as well as TβRI-overexpressing MCs because the 
parental MCs express the lowest or undetectable level of TβRI 
and TβRII among the four human skin cell types (Fig. 4 A). 
Figure 5.  Up-regulation of T𝗃RII converts epi-
dermal HK motility to become TGF𝗃3 sensitive 
just like dermal cells. (A) Lentiviral infection 
  offered >90% gene transduction efﬁ  ciency in 
DFs, MCs, HDMECs, and HKs. 48 h after in-
fection with pRRLsin-CMV-EGFP, the plates 
were analyzed under ﬂ  uorescence microscopy 
and photographed. The cells were suspended 
by trypsin and subjected to FACS analyses for 
measurement of the gene transduction efﬁ  -
ciency (percentage of green cells/total cells). 
(B) Elevated expression of TβRII in HKs after 
pRRLsin-TβRII infection (lane 5) in comparison 
with the endogenous TβRII expression in HKs 
(lane 2), DFs (lane 3), and HDMECs (lane 1). 
Equal amounts of cell extracts of the indicated 
cell types were blotted with anti-TβRII antibody 
(a) or anti–β-actin antibody (b). (C) TβRII-KD 
blocks TGFβ3-stimulated Smad2/3 phosphory-
lation in HKs. The HKs, infected with vector, 
wild-type TβRII, or TβRII-KD, were untreated or 
treated with 2.5 ng/ml TGFβ3 for 45 min and 
analyzed for the phosphorylation of Smad2/3 
similar to the assays shown in Fig. 4 (C and D). 
(D) Elevated expression of TβRII-KD in HKs af-
ter pRRLsin-CMV–TβRII-KD infection (lane 3) in 
comparison with elevated wild-type TβRII ex-
pression (lane 2) and the endogenous TβRII 
expression in HKs (lane 1). (E) Elevated 
  expression of TβRIII in HKs (lane 4 vs. lane 3) 
after pRRLsin-CMV-TβRIII infection in compari-
son with endogenous TβRIII expression in DFs 
(lane 2) and HDMECs (lane 1). (F) The afore-
mentioned TβR-engineered HKs were tested for 
their migratory responses to plasma, serum, or 
TGFα with or without 0.5 ng/ml TGFβ3 in col-
loidal gold migration assays. MIs are shown  . 
This experiment was repeated three times. 
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As shown in Fig. 6 A, the parental MCs expressed a lower level 
of TβRI (lane 1) than both HKs (lane 3) and DFs (lane 4). 
However, the pRRLsinhCMV-TβRI virus-infected MCs showed 
an increased expression of TβRI (Fig. 6 A, lane 2) similar to the 
TβRI expression in HKs and DFs. Similarly, as shown in Fig. 
6 B, parental MCs expressed low or undetectable levels of 
TβRII (Fig. 6 B, lane 1). pRRLsinhCMV-TβRII virus infection 
 increased  the  TβRII expression in MCs (Fig. 6 B, lane 2) to a 
similar level seen in DFs (Fig. 6 B, lane 3).
We then tested the migratory response of these cells to 
plasma and serum. As shown in Fig. 6 C, parental MC migration 
was equally stimulated by plasma and serum (bars 2 and 3 vs. 
bar 1) and was not sensitive to TGFβ3 (bar 4). The increased 
expression of TβRI in MCs had no effect on cell migration in 
response to plasma (Fig. 6 C, bar 6), serum (Fig. 6 C, bar 7), or 
plasma plus TGFβ3 (Fig. 6 C, bar 8). In contrast, the migration 
of TβRII-overexpressing MCs became converted from TGFβ 
insensitive to TGFβ sensitive, in which serum strongly inhibited 
migration of the cells (Fig. 6 C, bar 11 vs. bar 3). In addition, 
TGFβ3 completely blocked the plasma-induced migration 
(Fig. 6 C, bar 12 vs. bar 4).
Higher T𝗃RII levels make dermal cells 
sensitive to both antimotility 
and antiproliferation signals 
of human serum and TGF𝗃3
To reversely confi  rm the determining role for TβRII levels 
of expression, we wanted to down-regulate the endogenous 
TβRII expression in DFs and HDMECs to the similar level 
observed in HKs and tested whether these TβRII–down-
  regulated dermal cells would become refractory to the antimo-
tility effect of serum and TGFβ3 just like the epidermal HKs 
and MCs. The FG-12 system, a lentiviral backbone carrying a 
short inhibitory RNA (siRNA) expression cassette (Qin et al., 
2003), was used to transduce siRNA against human TβRII into 
DFs and HDMECs. To select the optimal virus titer, we 
  infected DFs and HDMECs with various dilutions (vol/vol) of 
the   original FG-12–TGFβ-RII–siRNA virus stock ( 4–7 × 10
6 
transduction units/ml). As shown in Fig. 7 A, infection of DFs 
(a) with 50% of the original virus stock (lane 3) reduced 
the TβRII expression in DFs (lane 6) to the similar level 
  observed in HKs (lanes 1). Similar results were obtained in 
HDMECs with 50% of the virus stock (Fig. 7 B, lane 4 vs. lane 1). 
The dilutions of the virus stocks did not cause any signifi  cantly 
compromised transduction effi  ciency. As shown in Fig. 7 C, 
the transduction effi  ciencies for 50% (1:1) or less dilutions 
were all >90%, as indicated by the coexpressed GFP for both 
HDMECs (a–c) and DFs (e–g). Only 25% (1:4) or higher  diluted 
viruses showed a signifi   cant decrease in the transduction 
 effi  ciency (Fig. 7 C, d and h).
Therefore, we chose 50% diluted virus stock to infect DFs 
and HDMECs for further migration assays. As shown in Fig. 7 D, 
in the vector- and control lac-Z–siRNA-infected DFs, plasma 
stimulated cell migration (bars 2 and 6), whereas serum and 
TGFβ3 inhibited cell migration (bars 3, 4, 7, and 8). However, 
in TβRII–down-regulated DFs, neither serum nor TGFβ3 was 
able to inhibit the cell migration (Fig. 7 D, bars 11 and 12 vs. 
bars 3 and 4). Instead, the cells responded to both plasma and 
  serum as promotility agents (Fig. 7 D, bars 11 and 12). Similarly, 
in HDMECs, down-regulation of TβRII converted the cells 
from serum- and TGFβ3-sensitive cells to TGFβ3-insensitive 
cells just like epidermal HKs and MCs. As shown in Fig. 7 E, 
migration of the HDMEC–RII–siRNA cells became insensitive 
to the antimotility effect of serum or TGFβ3 (Fig. 7 E, bars 11 
and 12 vs. bars 7 and 8). Moreover, both plasma (Fig. 7 E, bar 10) 
and serum (Fig. 7 E, bar 11) became promotility agents for the 
cells. In conjunction with our previous study reporting that 
TGFβ blocks both proliferation and migration of DFs (Sarret 
et al., 1992), these fi  ndings again indicate that the levels of 
TβRII determine the uptake of the antimotility signals, the anti-
proliferation signals, or both of TGFβ3.
Discussion
This study is a signifi   cant departure from previous wound-
  healing studies using human skin cells (for review see Li et al., 
2004c). First, those studies used bovine pituitary extract (BPE) 
or FBS as the stimuli of human skin cell migration and prolifera-
tion. However, human skin cells are never in contact in real life 
with BPE or FBS. In fact, neither BPE nor FBS resembles  human 
serum to differentially affect human dermal and epidermal cells. 
Second, because previous studies often focused on a single type 
of human skin cell or cell line, little could be learned about 
  coordinated migration of the multitype skin cells, which are 
  simultaneously present in the wound bed in vivo. Because of 
Figure 6.  Up-regulation of T𝗃RII, but not T𝗃RI, causes epidermal MC 
  motility to become TGF𝗃3 sensitive. (A) Elevated expression of TβRI in MCs 
(lane 2 vs. lane 1) after pRRLsin-CMV-TβRI infection in comparison with 
  endogenous TβRI expression in HKs (lane 3) and DFs (lane 4). (B) Elevated 
expression of TβRII in MCs (lane 2 vs. lane 1) after pRRLsin-CMV-TβRII 
  infection in comparison with endogenous TβRII expression in DFs (lane 3). 
(C) Migration of MCs with vector control (bars 1–4), overexpressing TβRI 
(bars 5–8), or overexpressing TβRII (bars 9–12) in the presence of plasma, 
serum, or plasma plus 0.5 ng/ml TGFβ3. Error bars represent SEM.TGFβ3 DETERMINES SKIN CELL MOTILITY ORDER • BANDYOPADHYAY ET AL. 1101
these new approaches, the results of this study unveil a previ-
ously unrecognized function for the naturally occurring plasma→
serum→plasma transition along the classical four phases of skin 
wound healing. A schematic representation of the key fi  ndings is 
shown in Fig. 8. When skin is acutely wounded, whereas plasma 
is still not fully converted to serum, DFs and HDMECs may fi  rst 
migrate into the wound over provisional ECM. In contrast, the 
epidermal cell migration (i.e., reepithelialization) has yet to take 
place because of the lack of HK   promotility activity in plasma 
(step 0). Then, the transition to serum quickly stops dermal cell 
migration by increasing the TGFβ3 level (fi  rst step) and, at the 
same time, promotes HK migration by newly acquired HK pro-
motility factors, predominantly TGFα (second step; Li, et al., 
2006). The selective   inhibition of dermal cell migration by 
TGFβ3 from serum   results from the higher TβRII expression 
levels in these cells, and, in contrast, the escape of inhibition by 
the epidermal cells is granted by   either the lower (HKs) or unde-
tectable (MCs) TβRII levels in the epidermal cells. After the 
wound heals,   serum transforms back to plasma, which resumes 
DF and   HDMEC migration into the newly healed wound for the 
fi  nal phase of wound healing,   remodeling, and angiogenesis 
(third step). Therefore, this study has provided a mechanism by 
which the orderly migration of three major skin cell types take 
place   during wound healing.
The main TGFβ in human serum was thought to come 
from platelet degranulation, in which TGFβ1 is the only  isoform 
present in the α granules of platelets (Assoian et al., 1983; 
  Roberts and Sporn, 1996). However, human serum but not 
plasma was reported to contain TGFβ3 at a concentration 
range of 1–2 ng/ml (Grainger et al., 2000; Hering et al., 2001), 
Figure 7.  Down-regulation of T𝗃RII causes dermal DF and HDMEC motility to become TGF𝗃3 insensitive just like the epidermal cells. DFs and HDMECs 
were infected with various dilutions (vol/vol) of the lentivirus (FG-12) carrying an siRNA against TβRII. After 48 h, the cells were ﬁ  rst analyzed for down-
regulation of the endogenous TβRII before being subjected to migration assays. (A) 50% dilution of the original virus stock decreases TβRII expression in 
DFs (a, lane 6) to the level similar to HKs (a, lane 3 vs. lane 1). (B) The same dilution of the virus stock decreases the TβRII expression in HDMECs (c, lane 6) 
to the similar level in HKs (c, lane 3 vs. lane 1). (C) Coexpressed GFP and FACS analyses show no signiﬁ  cant reduction in gene transduction efﬁ  ciency in 
HDMECs (a–c) or DFs (e–g) unless the virus stock is diluted to 25% or further (d and h). (D and E) DF and HDMEC cells 48 h after infection with 50% of 
the original virus stocks of vector alone, lac-Z–siRNA, and TβRII-siRNA were subjected to colloidal gold migration assays in the absence or presence of 
plasma, serum, and plasma plus TGFβ3. MIs are shown. These migration experiments were repeated three times. Error bars represent SEM.JCB • VOLUME 172 • NUMBER 7 • 2006  1102
which likely comes from the blood leukocytes (Assoian et al., 
1987; Grotendorst et al., 1989; Nishimura et al., 1998). An in-
crease in TGFβ2 in serum has also been reported (Bellone et al. 
2005). Because of technical diffi  culties, there is still a lack of 
consensus in the exact levels of TGFβ in human plasma and 
  serum (Roberts, 1998; Piek et al., 1999; Grainger et al., 2000). 
First, it is extremely diffi  cult to collect platelet-free plasma and 
to completely prevent degranulation of the contaminated plate-
lets because platelets tend to resuspend during plasma prepara-
tion (Assoian et al., 1984; Sporn and Roberts, 1990). Second, a 
wide range of methods for measuring TGFβ (mostly for TGFβ1) 
has been used. The bioassay-based measurements selectively 
measure the amount of the biologically active TGFβ, and, there-
fore, they provide data on the “operational” TGFβ (Gentry 
et al., 1988; Garrigue-Antar et al., 1995). On the other hand, the 
antibody-based ELISA assays detect the total amount of free 
TGFβ. In the latter case, during the dilution steps of these 
 assays,  some  TGFβ peptides dissociate from their noncovalently 
bound complexes and become detectable. This dissociation 
could also cause nonlinear curves of the assays (Grainger et al., 
2000). Third, because the half-life of an active TGFβ peptide is 
only 2–3 min, it is diffi  cult to determine whether the detected 
amount of TGFβ represents the steady-state level or in vitro 
broken down level of TGFβ (Roberts, 1998; Piek et al., 1999). 
Finally, the wide variations on age, gender, or racial background 
of the selected donors for the human subjects also contributed to 
the variations in detected TGFβ.
The three mammalian TGFβ isoforms TGFβ1, TGFβ2, 
and TGFβ3 bind to and transmit signals via the heteromeric 
complex of TβRII and TβRI/activin receptor-like kinase (Alk) 
serine/threonine kinases (Miyazono, 2000; Derynck and Zhang, 
2003; Shi and Massagué, 2003). However, the three mammalian 
TGFβ isoforms diverge signifi  cantly in their potency as growth 
inhibitors in vitro as a result of differences in receptor recogni-
tions and binding to extracellular antagonists (Cheifetz et al., 
1990; Goumans et al., 2002). In vascular endothelial cells and 
hematopoietic progenitor cells, TGFβ1 and TGFβ3 showed 
stronger growth-inhibitory   effects than TGFβ2 (Ohta et al., 
1987; Cheifetz et al., 1992).   Roberts et al. (1990) showed that 
TGFβ3 was 10-fold more active than TGFβ2 in mesoderm in-
duction in Xenopus laevis, whereas TGFβ1 had little effect. Ren 
et al. (1999) showed that TGFβ3 but not TGFβ1 and TGFβ2 
induced the expression of presenilin-1, a familial Alzheimer’s 
disease–linked gene, in neurons and astrocytes. Moreover, 
ex vivo wound-healing studies showed that TGFβ1 and TGFβ2
cause a fi  brotic scarring response and that TGFβ3 elicits scar-
free or regenerative healing responses (for   review see Ferguson 
and O’Kane, 2004). However, discrepancies have also been re-
ported (Wu et al., 1997; Shah et al., 1999).
Consistent with the divergence in vitro, knockout studies 
in mice showed that TGFβ1, TGFβ2, and TGFβ3 are not func-
tionally redundant (for review see Roberts and Sporn, 1992; 
  Attisano and Wrana, 1996; Dünker and Krieglstein, 2000). 
  Unfortunately, skin wound-healing studies using these TGFβ 
knockout mice were compromised by severe developmental 
  defects in the mice. TGFβ2 and TGFβ3 knockout mice die 
  during or shortly after birth (Proetzel et al., 1995; Kaartinen 
et al., 1995; Sanford et al., 1997). While one half of the TGFβ1 
knockout mice are born alive, they undergo early postnatal 
death (3 wk) as a result of a massive infi  ltration of infl  ammatory 
lymphocytes and macrophages onto several organs. The other 
half dies in utero because of defects in vasculogenesis and 
  hematopoiesis (Shull et al., 1992; Kulkarni et al., 1993). None-
theless, Koch et al. (2000) reported little impairment in wound 
healing in <10-d-old neonatal TGFβ1 knockout (Tgfβ1
−/−) 
mice and in 30-d-old Tgfβ1
−/− mice treated with rapamycin, an 
immune suppressant. In contrast, Crowe et al. (2000) reported a 
1-wk delay in each of the major phases of wound healing in 
 immunodefi  cient TGFβ1 knockout mice (Tgfβ
−/−/Scid
−/− mice; 
Crowe et al., 2000). The reason for the discrepancy is unclear.
Figure 8.  A schematic representation of how the plasma→
serum→plasma transitions coordinate the orderly skin cell 
migration during wound healing. Three major types of skin 
cells—HKs, DFs, and HDMECs—are shown here, as indi-
cated by different colors. The dermal cells express higher lev-
els of TβRII (symbolized by Y) than the epidermal cells. 
Therefore, the dermal cells are sensitive to the anti-promotility 
effect of TGFβ3 (red stars), whose concentration increases af-
ter the transition from plasma to serum in the wound bed. 
Contributions by other cell types and matrix components to 
skin wound healing are omitted for the sake of simplicity but 
not reality. The relative numbers and proportions of the vari-
ous types of cells do not quantitatively reﬂ   ect those in real 
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Our study showed that the TβR profi  les, especially the 
differences in the levels of TβRII, in three major human skin 
cell types as well as MCs determine their migratory responses 
to plasma or serum, respectively. How the quantitative differ-
ences in the TβRII levels are translated into the distinct signaling 
outcomes remain to be studied. We detected little differences 
in Smad2/3 activation between the dermal and epidermal cell 
types in response to various doses of TGFβ3. However, a 
 difference in the kinetics of Smad2/3 activation between TGFβ-
sensitive DFs and HDMECs and TGFβ-insensitive HKs was 
reproducibly observed. TGFβ3 appeared to stimulate a more 
sustained phosphorylation of Smad2/3 in the epidermal cells in 
comparison with the TGFβ3-stimulated kinetics of Smad2/3 
phosphorylation in the dermal cells. Furthermore, we found 
that the difference in the kinetics of Smad2/3 activation was 
caused by the difference in TβRII levels between dermal and 
epidermal cells (unpublished data). Whether this difference 
accounts for the distinct physiologic responses of dermal 
  versus epidermal cells remains to be studied. It is equally possi-
ble that TβRII might mediate the antimotility   effect of TGFβ3 
via a Smad-independent signaling pathway (Derynck and 
Zhang, 2003).
Materials and methods
Primary human neonatal DFs, HDMECs, HKs, and MCs were purchased 
from Clonetics. HKs were cultured in the EpiLife medium supplemented 
with the HKGS Kit (Cascade Biologics). MCs were maintained in Medium 
154 supplemented with human MC growth supplement (Cascade 
  Biologics). DFs were cultured in DME supplemented with 10% FBS. 
  HDMECs were cultured in GF-supplemented Medium 131 (Cascade 
  Biologics). Third or fourth passages of the cell cultures were used in all 
experiments. Human plasma and serum collected from a variety of donors 
were   purchased from Sigma-Aldrich. Human recombinant TGFβ1, TGFβ2, 
and TGFβ3 were purchased from R&D Systems. Anti–human TGFβ (1, 2, 
and 3) pan-neutralizing antibody and neutralizing antibodies speciﬁ  cally 
against human TGFβ1, TGFβ2, or TGFβ3 were obtained from R&D 
  Systems. Human TβR (I and II) cDNAs were obtained from T. Imamura 
and K. Miyazono (Japanese Foundation for Cancer Research, Tokyo, 
  Japan). TβRIII cDNA was a gift from J. Massagué (Memorial Sloan-
  Kettering Cancer Center, New York, NY). TβRII-KD cDNA was a gift from 
K. Luo (University of California, Berkeley, Berkeley, CA). Antibodies 
against TβRI/Alk5, TβRII, and TβRIII/betaglycan were either gifts of J. Li 
(House Ear Institute, Los Angeles, CA) or were obtained from Cell Signal-
ing   Technology, Santa Cruz Biotechnology, Inc., and R&D Systems, re-
spectively. DAPI and rhodamine-conjugated phalloidin were purchased 
from Sigma-Aldrich. The FG-12 system was provided by I. Chen (Univer-
sity of California, Los Angeles, Los Angeles, CA). Rat type I collagen was 
purchased from BD Biosciences. Antiphospho-Samd2 (ser-465/467) anti-
body (AB3849) was purchased from Chemicon International. Anti–β-actin 
antibody was obtained from Cell Signaling Technology, and the Plasmid 
Midi Kit was purchased from QIAGEN. XL-10 Gold ultracompetent cells 
were purchased from Stratagene. All other reagents and supplies, unless 
  indicated, were obtained from VWR or Sigma-Aldrich.
Cell migration assay
The colloidal gold migration assay was performed as previously described 
(Li et al., 2004b).
Statistical analyses
The methodology to determine differences in MIs between experiments has 
been previously described (Chen et al., 1993). In brief, statistical analyses 
of the differences in MIs between triplicate sets of experimental conditions 
were performed using Microsoft Excel. Conﬁ   rmation of a difference in 
  migration as statistically signiﬁ  cant requires rejection of the null hypothesis 
of no difference between mean MIs obtained from replicate sets at the 
P ≥ 0.05 levels with the t test.
Test and use of anti-TGF𝗃 neutralizing antibodies
Based on the technical data provided by manufacturers, we performed 
  titration experiments to obtain the highest concentration for each antibody 
that did not yet cross-react with the other two TGFβ isoforms. In addition, 
because the three antibodies’ afﬁ  nities (the ratio of antibody amount vs. 
antigen amount) toward their antigens are different, we obtained the con-
centrations (micrograms/milliliters) for all of the anti-TGFβ antibodies that 
neutralize a similar amount of their corresponding antigens (i.e., TGFβ1, 
TGFβ2, and TGFβ3). For example, 0.2 μg/ml of anti-TGFβ1, 0.08 μg/ml 
of anti-TGFβ2, and 0.1 μg/ml of anti-TGFβ3 all blocked the function of 
 5 ng/ml TGFβ1, TGFβ2, and TGFβ3, respectively, without cross-reactions. 
To achieve the maximum neutralizing effects, plasma- or serum-containing 
media were preincubated with the antibodies for 30 min before being 
added to migration wells.
cDNA subcloning, production of lentiviral stocks, and infection
The lentivirus-derived vector pRRLsinhCMV was inserted with cDNAs  encoding 
EGFP (at EcoRV), human TβRI (at EcoRI and SacII), human TβRII (at BamHI), 
human TβRIII (at XbaI and EcoRI), and human TβRII-KD (at BamHI and EcoRI). 
For the PCR-ampliﬁ   ed cDNA inserts (TβRIII and TGFβRII-KD), their DNA 
  sequences in pRRLsinhCMV were conﬁ  rmed by DNA   sequencing. These con-
structs were used to cotransfect 293T cells together with packaging vectors 
pCMV∆R8.2 and pMDG as previously described (Chen et al. 2003). Typical 
viral titers were 1–7 × 10
6 transduction units/ml without concentration and 
5 × 10
7–10
8 after ultracentrifugation using GFP as the marker directly mea-
sured by FACS analysis. Cell infection and infection efﬁ  ciency, as monitored 
by EGFP expression, were performed as previously described (Li et al., 
2004a). The cells were subjected to biochemical and cell migration experi-
ments 48 h after infection. The images of GFP-expressing cells were analyzed 
and recorded by a ﬂ  uorescence microscope (Axiovert 25; Carl Zeiss Micro-
Imaging, Inc.) with an attached camera (type 12; model SC35; Olympus).
Measurement of transgene expression levels
Expression of TβR gene products were detected by immunoblotting the lysates 
of infected cells with antibodies against corresponding TβRs. The lower part 
of the same membranes were blotted with an anti–β-actin antibody as the 
control for equal sample loading. Selected autoradiographs with unsaturated 
exposure among the speciﬁ  c signals were used to assess fold increases (over 
their corresponding β-actin bands) by scanning densitometry. Means from 
three different exposures of each experiment were calculated against the in-
dependent gene product control as an averaged ratio (Li et al., 2004a).
Sequential staining of human skin tissue with antibodies, phalloidin, 
and DAPI
The detailed procedures are as previously described (Woodley et al., 
2004). For immunostaining with anti-TβR antibodies, we used the diamond 
cutter to make a highly visible circle around the tissue on the back of the 
slides and then washed and air dried the slides. The tissue specimen on 
slides was ﬁ  xed with  25 μl acetone for 5 min, washed with PBS, and 
blocked in 25 μl of the blocking reagent (1:10 dilution of normal goat se-
rum, 0.05% Tween 20, 0.05 Triton X-100, and 1% BSA in PBS) for 60 min 
in a H2O humidiﬁ  ed chamber. The slides were washed with PBS and incu-
bated with primary antibodies for 60–120 min. We washed the slides 
three times (7 min each) in PBS, incubated with FITC-conjugated secondary 
antibody added directly onto the tissue area, and covered the slides to pre-
vent light (for the rest of the procedures). Slides were washed in PBS twice 
and air dried. To continue with phalloidin staining, the tissue specimens 
were ﬁ  xed with 4% formaldehyde in PBS for 15 min, washed with PBS 
twice, and permeabilized with 0.1% Triton X-100 in PBS for 5 min. After 
washing with PBS, the tissue specimen was blocked with 1% BSA in PBS 
for 30 min and incubated with 1 μg/ml rhodamine-labeled phalloidin in 
1% BSA in PBS for 1 h. The slides were washed with PBS and air dried. To 
carry out the ﬁ  nal staining with DAPI, we directly added prepared DAPI so-
lution (1–2 μg/ml DAPI in 40% glycerol) to the tissue areas, mounted these 
with coverslips, and sealed them with nail polish. The results were ana-
lyzed under a microscope (100× at −20°C; TE-2000U Eclipse; Nikon) 
with sequential applications of the following ﬂ  uorochromes: green (FITC), 
blue (DAPI), and red (phalloidin) in the absence of any imaging medium. 
The images were recorded in JPEG by an attached camera (TE-2000U; 
Nikon) using MetaMorph software (version-6.2rb; Universal Imaging).
siRNA, lentiviral infection delivery, and quantitation 
of transduction efﬁ  ciency
We used the siRNA Selection Program as described previously to identify 
possible target sequences (Yuan et al., 2004). Six potential sites were 
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double-stranded siRNA in the down-regulation of PKCδ was measured by 
transfecting 293T cells and immunoblotting the cell lysates with corre-
sponding anti-TβRII antibodies. The most potent one was then cloned into 
the lentiviral siRNA delivery vector FG-12 as previously described (Qin 
et al., 2003). The gene transduction efﬁ  ciency was analyzed under a 
ﬂ  uorescence microscope (Axioplan; Carl Zeiss MicroImaging, Inc.) with 
an MRm camera system (Axiocam; Carl Zeiss MicroImaging, Inc.) and 
by FACS analysis for a coexpressed GFP gene marker on the same vec-
tor. The selected siRNA sequence (sense) against human TβRII for FG-12 
cloning was G  A  C  C  U  C  A  A  G  A  G  C  U  C  C  A  A  U  A  , which effectively down-
regulated TβRII.
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